Aljahdali, Ieman A. M.
Ling, Xiang
Wu, Wenjie
Wang, Wenchao
Li, Dan
Zhang, Renyuan
Zhang, Emma
Stablewski, Aimee
Azrak, Rami
Li, Qingyong
Li, Fengzhi
Funding for this research was provided by:
PhD student tuition grant (Not applicable, Not applicable)
NIH/NCI Grants (R43CA221389, R43CA221389)
Zhejiang Provincial Natural Science Foundation of China (LQ23H300008)
National Key Research and Development Program of China (2022YFC2804104)
China Postdoctoral Science Foundation (2022M712823)
Pancreatic Cancer Action Network (24-CAT-LIFZ)
Mesothelioma Applied Research Foundation Grant (Not applicable)
Pancreatic Cancer Action Network (PanCAN) Translational Research Grant (20-65-FENG)
donation funds from cancer patients and their family members (Not applicable)
Article History
Received: 29 May 2025
Accepted: 16 September 2025
First Online: 21 October 2025
Declarations
:
: Competing interests: FL118 and FL118 core structure-based analogues will be further developed in Canget BioTekpharma LLC ( ), a Roswell Park Cancer Institute spinoff company. FL and XL are two of the initial eighteen investors of Canget to develop FL118 and FL118 core structure-relevant anticancer agents. FL is a full-time employee at Roswell Park Comprehensive Cancer Center (RPCCC) with an adjunct role acting as Chief Scientific Officer (CSO) in the Roswell Park spinoff Canget. FL has a conflict of interest (COI) management plan in place with Roswell Park.
: Not applicable.
: Not applicable.
: FL118 and FL118 core structure-based analogues will be further developed in Canget BioTekpharma LLC ( ), a Roswell Park Cancer Institute spinoff company. FL and XL are two of the initial eighteen investors of Canget to develop FL118 and FL118 core structure-relevant anticancer agents. FL is a full-time employee at Roswell Park Comprehensive Cancer Center (RPCCC) with an adjunct role acting as Chief Scientific Officer (CSO) in the Roswell Park spinoff Canget. FL has a conflict of interest (COI) management plan in place with Roswell Park.